Trillium Therapeutics Inc. (TSE:TRIL – Get Free Report) shares rose 0.5% during mid-day trading on Monday . The stock traded as high as C$23.45 and last traded at C$23.33. Approximately 60,423 shares were traded during trading, a decline of 64% from the average daily volume of 166,586 shares. The stock had previously closed at C$23.22.
Trillium Therapeutics Trading Up 0.5 %
The firm’s 50 day moving average price is C$23.33. The company has a debt-to-equity ratio of 0.27, a quick ratio of 11.54 and a current ratio of 12.04. The company has a market capitalization of C$2.45 billion and a PE ratio of -34.06.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.
Further Reading
- Five stocks we like better than Trillium Therapeutics
- Quiet Period Expirations Explained
- How to Invest in Silver: A Beginner’s Guide
- What is the Shanghai Stock Exchange Composite Index?
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Why Invest in High-Yield Dividend Stocks?
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
